These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 2872569)
1. Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363,586) in insulin-dependent diabetes mellitus. Gottesman I; Tobert J; Vandlen R; Gerich J Life Sci; 1986 Jun; 38(24):2211-9. PubMed ID: 2872569 [TBL] [Abstract][Full Text] [Related]
2. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus. Dimitriadis G; Tessari P; Gerich J Metabolism; 1983 Oct; 32(10):987-92. PubMed ID: 6136893 [TBL] [Abstract][Full Text] [Related]
3. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Spinas GA; Bock A; Keller U Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093 [TBL] [Abstract][Full Text] [Related]
4. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics. Neuhaus C; Kerner W; Maier V; Pfeiffer EF Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066 [TBL] [Abstract][Full Text] [Related]
5. Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somatostatin analogue (L363,586). Bolli GB; Gottesman IS; Gerich JE Horm Res; 1988; 29(2-3):95-8. PubMed ID: 2900206 [TBL] [Abstract][Full Text] [Related]
6. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas. Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329 [TBL] [Abstract][Full Text] [Related]
7. Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog. Campbell PJ; Bolli GB; Gerich JE Metabolism; 1988 Jan; 37(1):34-7. PubMed ID: 2892113 [TBL] [Abstract][Full Text] [Related]
8. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes. Osei K; O'Dorisio TM; Malarkey WB; Cataland S J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644 [TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. Osei K; O'Dorisio TM; Malarkey WB; Craig EL; Cataland S Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340 [TBL] [Abstract][Full Text] [Related]
10. Effect of a zinc phosphate suspension of a long-acting somatostatin analog on postprandial plasma glucose, triglyceride and glucagon concentrations in alloxan diabetic dogs. Martin C; Wallum B; Krom B; Hall L; Gerich J Life Sci; 1984 Dec; 35(26):2627-33. PubMed ID: 6151111 [TBL] [Abstract][Full Text] [Related]
11. Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes. Davies RR; Miller M; Turner SJ; Watson M; McGill A; Orskov H; Alberti KG; Johnston DG Clin Endocrinol (Oxf); 1986 Dec; 25(6):739-47. PubMed ID: 2888547 [TBL] [Abstract][Full Text] [Related]
12. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus. Dimitriadis G; Gerich J Horm Metab Res; 1985 Oct; 17(10):510-1. PubMed ID: 2866155 [TBL] [Abstract][Full Text] [Related]
13. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14. Hadjidakis DI; Raptis SA; Raptis AE; Karaiskos C; Souvatzoglou A; Diamantopoulos EJ Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770 [TBL] [Abstract][Full Text] [Related]
14. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients. Wajchenberg BL; Cesar FP; Leme CE; Borghi VC; Souza VC; Souza IT; Neto DG; Germek OA; Coy DH; Comaru-Schally AM Horm Metab Res; 1983 Oct; 15(10):471-4. PubMed ID: 6139329 [TBL] [Abstract][Full Text] [Related]
15. Effect of somatostatin on blood sugar, plasma growth hormone, and glucagon levels in diabetic children. Del Guercio MJ; di Natale B; Gargantini L; Garlaschi C; Chiumello G Diabetes; 1976 Jul; 25(7):550-3. PubMed ID: 1278605 [TBL] [Abstract][Full Text] [Related]
16. Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Paolisso G; Sgambato S; Passariello N; Scheen A; D'Onofrio F; Lefèbvre PJ Diabetes; 1987 May; 36(5):566-70. PubMed ID: 2883055 [TBL] [Abstract][Full Text] [Related]
17. 24-hour studies of the effects of somatostatin on the levels of plasma growth hormone, glucagon, and glucose in normal subjects and juvenile diabetics. Christensen SE; Hansen AP; Weeke J; Lundbaek K Diabetes; 1978 Mar; 27(3):300-6. PubMed ID: 640235 [TBL] [Abstract][Full Text] [Related]
18. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers. Aarsen RS; Bruining GJ; Grose WF; van Strik R; Lamberts SW; Harris AG Acta Endocrinol Suppl (Copenh); 1987; 286():45-53. PubMed ID: 2892337 [TBL] [Abstract][Full Text] [Related]
19. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal response to a mixed meal in acromegalic patients. Candrina R; Gussago A; Giustina G J Endocrinol Invest; 1988 Jan; 11(1):21-6. PubMed ID: 2896207 [TBL] [Abstract][Full Text] [Related]
20. Acute effect of the somatostatin analogue SMS-201995 on plasma glucose and triglycerides in insulin-dependent diabetic patients. Malerbi DA; de-Camargo JW; Cesar FP; Wajchenberg BL Braz J Med Biol Res; 1992; 25(6):593-600. PubMed ID: 1342235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]